RxDoctor Payments Data

John Allen, MD

Psychiatry · El Cajon, CANPI 1659382588

Payments from drug & device makers

$63,605in general payments, 2019–2025

Across 106 payments — averaging $600.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$44K
  • Teva Pharmaceuticals USA, Inc.$9K
  • Johnson & Johnson$6K
  • Janssen Scientific Affairs, LLC$3K
  • Neurocrine Biosciences, Inc.$154
  • Indivior Inc.$123
  • plus $187 from 3 others
$5,400in research payments, 2019–2025

Across 2 payments — averaging $2700.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alkermes, Inc.$5K

What the payments were for

  • Consulting fees$8,07513%
  • Speaking & faculty fees$47,87075%
  • Travel & lodging$1,5402%
  • Food & beverage$6,08910%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,605 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$113,453
Medicare patients
105
Services billed
1,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega HafyeraPaliperidone Palmitate73$1,550,199
AustedoDeutetrabenazine73$458,215
LybalviOlanzapine/Samidorphan Malate128$202,574
AristadaAripiprazole Lauroxil35$129,676
Invega SustennaPaliperidone Palmitate33$113,654
IngrezzaValbenazine Tosylate13$106,810
Paliperidone ErPaliperidone236$50,347
NuedextaDextromethorphan Hbr/Quinidine30$48,140
Divalproex Sodium ErDivalproex Sodium357$28,830
Clozapine414$28,006
Varenicline Tartrate87$21,300
Clozapine OdtClozapine67$19,332
OzempicSemaglutide18$17,618
RexultiBrexpiprazole11$15,214
AmantadineAmantadine Hcl234$11,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$9,479$458,21573 claims
Alkermes, Inc.Lybalvi, Aristada$44,437$332,250163 claims
Johnson & JohnsonInvega Sustenna$5,878$113,65433 claims
Neurocrine Biosciences, Inc.Ingrezza$154$106,81013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in El Cajon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →